HONG KONG, July 3, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") has announced the successful ...

Sigvotatug Vedotin is an ADC that targets integrin αvβ6-positive tumor cells. It has an engineered antibody that ensures high ...

Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford ...

ACROBiosystems has developed a series of specialized proteases for the screening and validation of ADC linkers, focusing on ...

On Wednesday, Biokin reported (PDF) positive topline results from a phase 3 trial of the ADC. The study enrolled patients ...

Cancer-hunting antibodies coupled with a natural compound found in soil microbes proved a powerful combination against an aggressive type of blood cancer, according to a new study from scientists at ...

The expert jury selected Dragan Grabulovski, Ph.D., Philipp Spycher, Ph.D., and Isabella Attinger-Toller, Ph.D. of Araris ...

The Asian tech sector is navigating a dynamic landscape, with regional markets reflecting a mix of resilience and cautious optimism amid ongoing global trade discussions and fluctuating economic ...

Kim Yong-joo, CEO of LigaChem Biosciences, announced plans to secure a total of 20 antibody-drug conjugate (ADC) candidates by 2027. In addition to the five currently under development, he plans to ...

New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

As global markets navigate through a period of mixed economic signals, with the U.S. indices hitting record highs and China's manufacturing sector showing signs of recovery despite ongoing trade ...

Datroway (datopotamab deruxtecan) is the first TROP2-directed therapy approved for advanced lung cancer in the U.S.